Tarsus: Commercial Engine Accelerates Revenue; Tactical Long on Continued Adoption

Hook / Thesis

Tarsus is no longer a pure play on future promise - the company is showing tangible commercial traction. Management’s marketing investment behind XDEMVY appears to be paying off: the company reported net product sales of $451.4 million in 2025, more than double the prior year, and gross margins around 93%. That kind of margin profile on a branded ophthalmology product is rare and materially changes the valuation conversation.

Technically, the stock is trading at $72.81 and is riding bullish momentum: price sits above the 10-, 20- and 50-day SMAs and the MACD is positive. Shorts remain meaningful, which raises the odds of episodic squeezes that can amplify upside. For traders who want defined risk with exposure to commercial upside and upcoming development milestones, this looks actionable.

What the company does and why the market should care

Tarsus Pharmaceuticals develops and commercializes therapies primarily in ophthalmology and infectious disease prevention. Its lead commercial product is XDEMVY, approved for Demodex blepharitis, and the pipeline includes TP-03 (Phase 2b/3 for Demodex blepharitis), TP-04 (ocular rosacea) and TP-05 (an oral tablet candidate aimed at preventing Lyme disease).

The reason the market should care is straightforward: XDEMVY has moved the company from R&D-only to a revenue-generating business. In 2025, the company reported $451.4 million in net product sales - more than double the prior year - and delivered gross margins around 93%. High margins plus visible top-line growth allow Tarsus to leverage fixed commercial costs and compress losses quickly as adoption scales.

Supportive numbers and what they imply

• Market capitalization is approximately $3.09 billion with an enterprise value near $2.98 billion.
• Valuation multiples are elevated: price-to-sales sits near 6.85 and EV-to-sales around 6.6x. Trailing EPS is negative at -$1.56, and free cash flow was negative $22.31 million most recently.
• Technical and liquidity backdrop: the stock is trading at $72.81, above the 10-day SMA ($70.59), 20-day SMA ($68.59) and 50-day SMA ($68.77). The RSI is a healthy 59.3 and MACD shows bullish momentum. Recent 52-week range: high $85.25 (12/09/2025) and low $38.51 (08/01/2025).
• Short interest has been material but trending down from prior peaks: 4,575,347 shares short as of 03/31/2026 with days-to-cover around 9.0 (using that settlement date’s average daily volume).

Valuation framing

At roughly $3.09 billion market cap and $451.4 million in 2025 product sales, the company is trading at about 6.8x trailing sales. That multiple looks full for a company still delivering net losses and negative FCF, but two caveats matter: first, gross margins near 93% imply most incremental revenue should drop to the bottom line once sales volumes cover fixed costs; second, the move from development-stage to commercially scaling changes the comparables set - Tarsus should be judged more like specialty ophthalmology franchises than early-stage biotechs.

Put another way, if XDEMVY continues to grow and management holds operating expenses in check, the elevated P/S multiple could compress over time as earnings and cash flow improve. Conversely, failure to sustain adoption or margin erosion would justify the current premium being pulled back.

Trade plan - actionable entry, target, stop, horizon

This is a directional, risk-defined long trade built around continued commercial momentum and a generally constructive technical setup.

• Entry: Buy at $72.81.
• Target: $85.00. This sits just under the 52-week high of $85.25 and reflects a pro-growth re-rating if quarterly results continue to show expanding sales and margins.
• Stop loss: $64.00. A break below $64 would take the stock below recent consolidation support and most short-term moving averages, signaling the commercial story may be slowing.
• Horizon: mid term (45 trading days). Expect to hold for approximately 45 trading days to give management time to report an earnings or sales update cadence and allow the market to digest continued adoption trends. If the trade runs quickly to target in under 10 trading days, consider trimming and tightening stops for the remaining position.

Why this setup makes sense

There are three practical reasons to favor a tactical long here:

• Commercial proof points: $451.4M in net product sales in 2025 with reported gross margins around 93% shifts Tarsus into a revenue-growth valuation story rather than pure binary clinical risk.
• Technicals and sentiment: price above multiple short-term SMAs, positive MACD and an RSI under 70 leave room for continued momentum. Short interest remains high enough to create asymmetric upside in the event of a positive catalyst.
• Reasonable exit: the 52-week high at $85.25 provides a clear upside target populated by recent price action and investor memory.

Catalysts to watch (2-5)

• Quarterly sales and margin updates confirming continued XDEMVY adoption and sustained ~90%+ gross margins.
• Any corporate presentations at investor conferences that quantify patient penetration or prescriber adoption rates.
• Progress readouts on TP-03, TP-04 or TP-05 that broaden the commercial runway or de-risk future launches.
• Management commentary on marketing ROI and inventory dynamics that point to sustainable demand rather than one-time stocking.

Risks and counterarguments

Every trade has risk. Here are the primary ones to monitor and at least one counterargument to the bullish view.

• Commercial adoption stalls: If XDEMVY growth decelerates or failed to repeat the 2025 acceleration, revenue guidance could fall short and multiples would re-rate lower quickly.
• Payer resistance or pricing pressure: Ophthalmology products face reimbursement scrutiny. Any kink in payer coverage or pricing concessions would hit the model and margin profile.
• Execution risk on international/adjacent launches: Scaling beyond the U.S. market or launching TP-04/TP-05 will require additional spend and regulatory progress. Execution missteps could sap investor enthusiasm.
• High valuation and negative FCF: The company trades at ~6.8x P/S with negative EPS (-$1.56) and negative FCF (-$22.31M). That leaves little margin for error and magnifies downside if growth slows.
• Short seller pressure and volatility: Material short interest historically created large intraday moves both ways; this increases risk for option sellers and leveraged positions.

Counterargument: One could reasonably argue that the 6.8x trailing sales multiple already prices in a sustained high-growth path and that any hiccup in 2026 revenue or margin expectations will force a sharp multiple contraction. Because EPS remains negative and FCF negative, pricing power and repeatable demand must be proven over multiple quarters before a higher valuation is justified.

What would change my mind

I will reconsider this bullish stance if any of the following occur:
- Quarterly product sales growth meaningfully decelerates from the 2025 ramp, or
- Gross margins drop materially below the mid-80s percentage range, signaling pricing or cost pressure, or
- The company guides materially lower for the next quarter or announces a major delay/negative result on a late-stage program that shifts investor attention back to binary clinical risk.

Conclusion

Tarsus’s transition from development-stage to commercial execution is real and measurable. $451.4M in 2025 product sales with ~93% gross margins is a strong combination and is reshaping the investment case from binary clinical hope to a growth-at-a-premium story. That said, valuation is not cheap and execution must remain consistent. For traders, a defined-risk long entry at $72.81 with a stop at $64.00 and a target near the 52-week high of $85.00 is a pragmatic way to participate in the upside while protecting capital if adoption stalls. Monitor sales cadence, margin stability and any comments on marketing ROI closely - those are the clearest near-term read-throughs on whether this commercial momentum is sustainable.

Trade snapshot: Long TARS at $72.81, target $85.00, stop $64.00. Horizon - mid term (45 trading days). Watch sales cadence and margin stability closely.